Eisai has completed construction of a new oral solid-dosage (OSD) production facility and an administration building at the site of its new Suzhou, China plant located within the Suzhou Industrial Park.

The newly completed OSD production facility stands three floors above ground and contains floor space of approximately 20,240 square meters. Its production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) is approximately double that of Eisai’s current Suzhou plant.

Operations are expected to begin in the second half of fiscal year 2018. The new OSD facility will handle the formulation and packaging of oral solid dosage products such as Methycobal (mecobalamin), a pure form of Vitamin B12, Aricept (donepezil), for treating dementia, and Pariet (rabeprazole), for treating gastroesophageal reflux disease, for the domestic Chinese market. The current plant will be closed after operations fully commence at the new OSD production facility.

Source: Eisai